Enter multiple symbols separated by commas

Amgen Shares Drop On More Anemia-Drug Fallout

Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.

Analysts at Bank of America and Robert W. Baird both downgraded their ratings to "neutral" after the U.S. Medicare health insurance program late on Monday proposed limiting payments for Amgen and Johnson & Johnson'sanemia drugs in response to safety concerns.

Baird analyst Christopher Raymond said the move by Medicare could lead to similar pressure from private insurers.

"We see the extent and nature of the coverage cuts as nothing less than stunning," Raymond wrote in a research note.

Amgen shares have now fallen more than 15% since before a U.S. Food and Drug Administration advisory panel last Thursday urged more limits and further study of the anemia drugs.

The shares fell as low as $52.36 earlier, the stock's lowest price since October 2004.

Looking ahead, Amgen shares could take a further hit if U.S. regulators were to approve a rival anemia drug from Roche AG. U.S. regulators are expected to act later this month on Roche's Mircera, which is in the same class as Amgen's franchise.

"Given everything that is surrounding the anemia drugs, we suspect there's a better-than-average chance that the FDA asks Roche for additional safety studies," said Jason Fox, a healthcare analyst with H&R Block Financial Advisors.

However, Fox said, if the FDA approves Mircera, "that would be another negative for the anemia franchise at Amgen."

Sales performance of its rheumatoid arthritis drug Enbrel in upcoming quarters also stands to affect Amgen shares, Fox said. He said data supporting Amgen's cancer treatment Vectibix also could impact the stock.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Hero miles for military members: Real estate magnate's plea

    Chairman of the Fisher House Foundation, Ken Fisher, discusses the Hero Miles program with CNBC's Dina Gusovsky. During Military Appreciation Month, Fisher is asking every traveler to donate 1,000 of their miles to replenish the Hero Miles programs that is in danger of running out.

  • Cramer shuts down this market's haters

    "Mad Money" host Jim Cramer on why this market can't stop, won't stop.

  • From the battlefield to the boardroom

    Your Grateful Nation is dedicated to helping Special Forces veterans enter the corporate world and Knot Standard provides complimentary suits to vets. Mad Money's Jim Cramer spoke with Rob Clapper, Your Grateful executive director; John Ballay, Knot Standard co-founder and president; Tej Gill, retired U.S. Navy Seal; and Darren McB, active duty U.S. Navy Seal.